Ultragenyx Pharmaceutical Inc. (RARE) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeeking Alpha • 09/10/25
RARE Reports Positive Long-Term Data From Metabolic Disorder StudyZacks Investment Research • 09/09/25
Ultragenyx Announces Positive Longer-term Data from Phase 3 Study of DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 09/08/25
Ultragenyx Pharmaceutical Inc. (RARE) Presents At Cantor Global Healthcare Conference 2025 TranscriptSeeking Alpha • 09/04/25
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RAREGlobeNewsWire • 08/29/25
Ultragenyx Initiates Rolling Submission of Biologics License Application (BLA) to U.S. FDA for DTX401 AAV Gene Therapy for the Treatment of Glycogen Storage Disease Type Ia (GSDIa)GlobeNewsWire • 08/18/25
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 08/05/25
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate UpdateGlobeNewsWire • 07/30/25
RARE Investors Have Opportunity to Join Ultragenyx Pharmaceutical Inc. Fraud Investigation with the Schall Law FirmBusiness Wire • 07/18/25
Ultragenyx Pharmaceuticals Gets CRL for UX111 Gene Therapy for MPS IIIAZacks Investment Research • 07/15/25
Ultragenyx Pharma Takes Another Hit As FDA Slaps Its Gene Therapy With A RejectionInvestors Business Daily • 07/14/25
Ultragenyx Pharmaceutical, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market SessionBenzinga • 07/14/25
Ultragenyx Receives Complete Response Letter from FDA for UX111 AAV Gene Therapy to Treat Sanfilippo Syndrome Type A (MPS IIIA)GlobeNewsWire • 07/11/25
Ultragenyx shares plunge after bone disorder trial misses key interim goalProactive Investors • 07/10/25
RARE, MREO Fall as Osteogenesis Study Likely to Continue Till Year EndZacks Investment Research • 07/10/25
Ultragenyx, Mereo Hammered For Their Surprise Miss In Brittle Bone DiseaseInvestors Business Daily • 07/10/25
Ultragenyx (RARE) Surges 5.1%: Is This an Indication of Further Gains?Zacks Investment Research • 07/10/25